Drugs / Rontalizumab
Rontalizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00541749 | Feb 2007 → ? | systemic lupus erythematosus | Genentech, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00962832 | Sep 2009 → Jan 2012 | systemic lupus erythematosus | Genentech, Inc. | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rontalizumab | “The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of rontalizumab, a humanized IgG1 monoclonal antibody that neutralizes IFNα, were assessed in a phase...” PMID 22833362 ↗ Nov 2012 |
| Known as | rhuMAb IFNalpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00541749 ↗ |
| Known as | rhuMAb interferon-α | “A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).” PMID 26038091 ↗ Jun 2015 |
| Action | Inhibit | “a humanized IgG1 monoclonal antibody that neutralizes IFNα” PMID 22833362 ↗ Nov 2012 |
| Modality | Monoclonal antibody | “a humanized IgG1 monoclonal antibody” PMID 22833362 ↗ Nov 2012 |
| Route | Intravenous | “administered via intravenous (IV) or subcutaneous routes.” PMID 22833362 ↗ Nov 2012 |
| Route | Subcutaneous | “administered via intravenous (IV) or subcutaneous routes.” PMID 22833362 ↗ Nov 2012 |